Loading...
Sareum Holdings plc
SAR.L•LSE
Healthcare
Biotechnology
£16.50
£-0.50(-2.94%)

Over the last four quarters, Sareum Holdings plc's revenue moved from $0.00 in Q2 2022 to $0.00 in Q4 2023. Operating income in Q4 2023 was -$2.06M, with a strong operating margin of N/A. Despite fluctuations in R&D and SG&A expenses, EBITDA for Sareum Holdings plc remained robust at -$2.02M, reflecting operational efficiency. Net income rose to -$911000.00, with an EPS of -$0.01. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan